Figure 4.
Intratumoral TIGIT+ CD8+ T-cell infiltration impairs CD8+ T-cell antitumor immunity in patients with muscle-invasive bladder cancer. (A) Expression of coinhibitory receptors (PD-1, n=24; CTLA-4, n=16; Tim-3, n=14; Lag-3, n=17) on CD8+ T-cells in TIGIT+ CD8+ T-cells high/low infiltration group. (B) Expression of proliferation marker (Ki-67, n=16) on CD8+ T-cells in TIGIT+ CD8+ T-cells high/low infiltration group. (C) Expression of effector cytokines (IFN-γ, n=23; TNF-α, n=23; IL-2, n=19) on CD8+ T-cells in TIGIT+ CD8+ T-cells high/low infiltration group. (D) Expression of cytotoxicity activation molecules (GZMB, n=19; CD107a, n=18; PRF-1, n=8) on CD8+ T-cells in TIGIT+ CD8+ T-cells high/low infiltration group. (E) Correlation between TIGIT+ CD8+ T-cells among CD45+ cells and IL-10+ CD8+ T-cells among CD45+ cells based on the results of flow cytometry. (F) Correlation between TIGIT+ CD8+ T-cells and IL-10+ cells based on the evaluation of immunohistochemistry staining. *P<0.05, **P<0.01 by Mann-Whitney U test. PD-1, program death-1; CTLA-4, cytotoxic T lymphocyte-associated antigen-4; IFN, interferon; IL, interleukin; GZMB, granzyme B; ns, no significance; TIGIT, T-cell immunoglobulin and ITIM domain.
